Uwell Biopharma, Inc. (7902)
TWSE TWSE Primary Summary
7902 Chart
Uwell Biopharma, Inc. (7902) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Uwell Biopharma, Inc. ever had a stock split?
Uwell Biopharma, Inc. Profile
| - Industry | - Sector | - CEO | TWSE Exchange | - ISIN |
| Taiwan Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Uwell Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative cancer immunotherapeutics. The organization specializes in engineered autologous cell therapies that utilize the patient's immune system to effectively target and eliminate cancer cells, with a particular emphasis on hematological tumors. Uwell's unique approach entails the genetic modification of a patient's T cells ex vivo to express chimeric antigen receptors (CARs). These CARs are designed to recognize native cancer antigens present on the surfaces of cancer cells, enabling the T cells to be reinfused into the patient to combat the disease. With its headquarters located in New Taipei City, Taiwan, Uwell Biopharma collaborates with various clinical teams operating across Taiwan, China, and Malaysia. Founded around 2020, the company actively contributes to oncology innovation in the biotechnology sector through pioneering cellular therapies, including CAR-T and CAR-NK technologies.
Products and Services
- Welgenaleucel (UWC19)
Welgenaleucel is a CD19-directed CAR-T therapy specifically developed for patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma and other B-cell malignancies. This product represents a significant advancement in the treatment options available for these types of blood cancers, leveraging the potent capabilities of engineered T cells to target and destroy malignant cells effectively.
- Preclinical Programs
Uwell Biopharma is also engaged in several preclinical development programs targeting various cancer types. Notable among these are therapeutic efforts aimed at HER2, which is associated with certain aggressive solid tumors, and the NKG2D CAR-T therapy, which is being explored for the treatment of glioblastoma. These programs highlight the company’s commitment to developing diverse and effective cellular therapies for different cancer indications, broadening the scope of immunotherapy treatments.
